Abstract
Objective: To study the efficacy of dasatinib treatment in different clinical stages of patients with chronic myeloid leukemia (CML). Methods: A total of 80 patients with chronic myeloid leukemia (CML) were selected for experimental research. According to different clinical stages, they were divided into chronic phase, accelerated phase and blast phase, and all of them were treated with dasatinib. Results: The complete cytogenetic response remission rate, complete hematologic remission rate, and major molecular biological remission rate in the chronic phase were significantly higher. Besides, the overall survival time and relapse-free survival time in the chronic phase were significantly longer, and the mortality during the follow-up period in the chronic phase was also significantly higher. Furthermore, the incidence of hematological adverse reactions of grades ? to ? in the chronic phase was significantly lower compared with the corresponding data of patients in the accelerated phase and blast phase with P<0.05. Conclusion: Different clinical stages of CML patients have different curative effects of dasatinib, which can effectively treat patients in chronic stage.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
